Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
India's top court hears challenges to ruling on women's entry into temple - 2Reconnecting with an old friend is a story of distance, loss and rediscovery
- 3Manual for Instructive Application for Youngsters
- 4A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- 5Are IDF reservists properly armed during post-war operations?
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Flu season is underway. What are common symptoms to watch for?
- People are getting their news from AI – and it’s altering their views
- Vote In favor of Your Favored IT Administration
- In blow to Lula, Brazil Congress revives controversial environmental bill
- A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- A Manual for Extravagant Vehicles Available in 2024
